Please select a Capability in order to start your service request.
Move Increases Size of Board to 10 MembersMay 7, 2014
SAN DIEGO, CA, May 7, 2014 /PRNewswire/ – CareFusion (NYSE:CFN), a leading global medical technology company, today announced that Supratim Bose has been elected as the 10th member of its board of directors, effective immediately.
Bose is currently executive vice president and president, Asia-Pacific, Middle East and Africa for Boston Scientific Corporation, a position he has held since January 2013. He joined Boston Scientific in December 2011 as executive vice president and president, Asia-Pacific and served in that role until he also assumed responsibility for the company's Middle East and Africa international units. Before joining Boston Scientific, Bose was founder and chief executive officer of Singapore-based Bose Consulting Group, which specialized in strategic management consulting services for the health care industry. Prior to that, he worked for nearly 30 years at Johnson & Johnson, where he concluded his tenure as company group chairman of its Medical Devices and Diagnostics business in 2009. Bose joined Johnson & Johnson Ltd. India in 1981, and held a variety of management positions of increasing responsibility.
"Supratim's deep knowledge and leadership experience in the Asia Pacific and international markets will be a valuable contribution as we look to grow our company outside of the U.S.," said Kieran Gallahue, chairman and CEO of CareFusion, "We are fortunate to have someone with his credentials in the medical device industry as part of our board of directors."
Bose will serve as an independent director and will stand for re-election at the company's annual meeting of stockholders, expected to take place in November.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.